调研速递|常山药业接受投资者调研 阿贝那肽上市进展成焦点

Group 1: Company Development and Strategy - The company will continue to focus on the heparin business, actively promoting the export of heparin preparations and raw materials, while flexibly responding to changes in the domestic market to achieve recovery and growth in the heparin business [1] - The company has identified innovative drugs as a key future development direction and is committed to transforming into an innovative drug enterprise [1] Group 2: Abebnate Progress and Sales Strategy - The submission of supplementary materials for Abebnate is a labor-intensive process and is not closely related to the issuance of the "Guidelines for the Clinical Trial of Recombinant Glucagon-like Peptide" [2] - The production capacity for Abebnate is currently over 20 million units annually, with the production facility previously built to meet the small-scale production needs for clinical trials [2] - The company is forming a marketing team for Abebnate and will gradually refine and adjust its marketing strategy based on the review progress and market conditions, but specific details cannot be disclosed at this time [2] Group 3: Other Relevant Issues - The technical cooperation with a U.S. company has not been affected by the political and economic situation, and the equity ratio of Changshan Kaijiejian remains unchanged during the renewal process [3] - The company currently has no specific plans for a targeted private placement, and the clinical trial for CSCJC3456 is ongoing, with no confirmed cancer type and no possibility of market launch in 2026 [3]